BACKGROUND: ETS-related gene (ERG) protein is present in 40-70% of prostate cancer and is correlated with TMPRSS2-ERG gene rearrangements. This study evaluated ERG expression at radical prostatectomy to determine whether it was predictive of earlier relapse or prostate cancer-specific mortality (PCSM). METHODS: One hundred patients who underwent radical prostatectomy at Virginia Mason in Seattle between 1991 and 1997 were identified. Recurrence was confirmed by tissue diagnosis or radiographic signs. PCSM was confirmed by death certificates. Thirty-three patients with metastases or PCSM were matched to patients without recurrence at a 1:2 ratio. Paraffin embedded tissue was stained with two anti-ERG monoclonal antibodies, EPR3864 and 9FY. Nuclear expression intensity was evaluated as present/absent, on a 4-point relative intensity scale, and as a composite score (0-300). RESULTS: Mean follow-up was 10.26 years. The two antibodies were highly correlated (P < 0.0001). Patients with higher ERG expression intensity and composite scores were significantly more likely to develop biochemical relapse, metastases, and PCSM. Kaplan-Meier survival curve analysis for the composite score of ERG expression revealed a significant association between higher ERG expression (EPR3864) and shorter PCa-specific survival (P = 0.047). CONCLUSIONS: While the presence of ERG expression at the time of surgery was not predictive of earlier relapse or PCSM, the relative intensity and composite score for ERG expression was prognostic for the development of biochemical relapse, metastases, and PCSM. Quantitative ERG scoring may be useful to identify patients who would benefit from adjuvant treatment or closer follow-up, allowing more accurate individual patient treatment plans.
BACKGROUND:ETS-related gene (ERG) protein is present in 40-70% of prostate cancer and is correlated with TMPRSS2-ERG gene rearrangements. This study evaluated ERG expression at radical prostatectomy to determine whether it was predictive of earlier relapse or prostate cancer-specific mortality (PCSM). METHODS: One hundred patients who underwent radical prostatectomy at Virginia Mason in Seattle between 1991 and 1997 were identified. Recurrence was confirmed by tissue diagnosis or radiographic signs. PCSM was confirmed by death certificates. Thirty-three patients with metastases or PCSM were matched to patients without recurrence at a 1:2 ratio. Paraffin embedded tissue was stained with two anti-ERG monoclonal antibodies, EPR3864 and 9FY. Nuclear expression intensity was evaluated as present/absent, on a 4-point relative intensity scale, and as a composite score (0-300). RESULTS: Mean follow-up was 10.26 years. The two antibodies were highly correlated (P < 0.0001). Patients with higher ERG expression intensity and composite scores were significantly more likely to develop biochemical relapse, metastases, and PCSM. Kaplan-Meier survival curve analysis for the composite score of ERG expression revealed a significant association between higher ERG expression (EPR3864) and shorter PCa-specific survival (P = 0.047). CONCLUSIONS: While the presence of ERG expression at the time of surgery was not predictive of earlier relapse or PCSM, the relative intensity and composite score for ERG expression was prognostic for the development of biochemical relapse, metastases, and PCSM. Quantitative ERG scoring may be useful to identify patients who would benefit from adjuvant treatment or closer follow-up, allowing more accurate individual patient treatment plans.
Authors: Alcides Chaux; Roula Albadine; Antoun Toubaji; Jessica Hicks; Alan Meeker; Elizabeth A Platz; Angelo M De Marzo; George J Netto Journal: Am J Surg Pathol Date: 2011-07 Impact factor: 6.394
Authors: Andreas Pettersson; Rebecca E Graff; Scott R Bauer; Michael J Pitt; Rosina T Lis; Edward C Stack; Neil E Martin; Lauren Kunz; Kathryn L Penney; Azra H Ligon; Catherine Suppan; Richard Flavin; Howard D Sesso; Jennifer R Rider; Christopher Sweeney; Meir J Stampfer; Michelangelo Fiorentino; Philip W Kantoff; Martin G Sanda; Edward L Giovannucci; Eric L Ding; Massimo Loda; Lorelei A Mucci Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-06-26 Impact factor: 4.254
Authors: Antoun Toubaji; Roula Albadine; Alan K Meeker; William B Isaacs; Tamara Lotan; Michael C Haffner; Alcides Chaux; Jonathan I Epstein; Misop Han; Patrick C Walsh; Alan W Partin; Angelo M De Marzo; Elizabeth A Platz; George J Netto Journal: Mod Pathol Date: 2011-07-08 Impact factor: 7.842
Authors: Kyung Park; Scott A Tomlins; Kumaran M Mudaliar; Ya-Lin Chiu; Raquel Esgueva; Rohit Mehra; Khalid Suleman; Sooryanarayana Varambally; John C Brenner; Theresa MacDonald; Abhishek Srivastava; Ashutosh K Tewari; Ubaradka Sathyanarayana; Dea Nagy; Gary Pestano; Lakshmi P Kunju; Francesca Demichelis; Arul M Chinnaiyan; Mark A Rubin Journal: Neoplasia Date: 2010-07 Impact factor: 5.715
Authors: A Marije Hoogland; Guido Jenster; Wytske M van Weerden; Jan Trapman; Theo van der Kwast; Monique J Roobol; Fritz H Schröder; Mark F Wildhagen; Geert Jlh van Leenders Journal: Mod Pathol Date: 2011-11-11 Impact factor: 7.842
Authors: Sarah Minner; Malaika Enodien; Hüseyin Sirma; Andreas M Luebke; Antje Krohn; Pascale S Mayer; Ronald Simon; Pierre Tennstedt; Julia Müller; Laura Scholz; Jan C Brase; Alvin Y Liu; Hartmut Schlüter; Klaus Pantel; Udo Schumacher; Carsten Bokemeyer; Thomas Steuber; Markus Graefen; Guido Sauter; Thorsten Schlomm Journal: Clin Cancer Res Date: 2011-07-26 Impact factor: 12.531
Authors: Karin G Hermans; Joost L Boormans; Delila Gasi; Geert J H L van Leenders; Guido Jenster; Paul C M S Verhagen; Jan Trapman Journal: Clin Cancer Res Date: 2009-10-13 Impact factor: 12.531
Authors: M Braun; D Goltz; D Adler; W Vogel; D Böhm; V Scheble; K Sotlar; F Fend; S-H Tan; A Dobi; G Kristiansen; N Wernert; S Perner Journal: Prostate Cancer Prostatic Dis Date: 2012-01-10 Impact factor: 5.554
Authors: A Marcell Szász; Attila Majoros; Philip Rosen; Shiv Srivastava; Albert Dobi; Attila Szendrői; Janina Kulka; Péter Nyirády Journal: Int Urol Nephrol Date: 2013-05-18 Impact factor: 2.370
Authors: Sung Han Kim; Soo Hee Kim; Jae Young Joung; Geon Kook Lee; Eun Kyung Hong; Kyung Min Kang; Ami Yu; Byung Ho Nam; Jinsoo Chung; Ho Kyung Seo; Weon Seo Park; Kang Hyun Lee Journal: PLoS One Date: 2015-04-21 Impact factor: 3.240
Authors: Caterina Mancarella; Irene Casanova-Salas; Ana Calatrava; Maria García-Flores; Cecilia Garofalo; Andrea Grilli; José Rubio-Briones; Katia Scotlandi; José Antonio López-Guerrero Journal: BMC Cancer Date: 2017-05-25 Impact factor: 4.430